Episode Details

STAAR Surgical crushed Q2 expectations with revenue up 3% over forecasts and a dramatic leap in operating margin from negative to over 10%. Analysts probed on future growth, China’s demand patterns, and pricing strategy—management stayed cautious but confident, emphasizing volume expansion over price hikes. Key hurdles ahead: scaling premium lens supply in China, relocating manufacturing to Switzerland to dodge tariffs, and fueling R&D for next-gen products. Stock dipped slightly to $24.65 post-earnings as investors eye whether the momentum can sustain.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/01e84a484b1ceb5b